University of Saskatchewan (USask) research, which has been published in Communications Biology, highlights the discovery of the lipid-lowering effects of nesfatin-1-like peptide (NLP).

Identification of NLP and understanding its lipid-lowering capabilities in human cells represent new advancements in the field of endocrinology making it a best choice for lipid disease treatment and therapeutic advancements. NLP is a hope for many metabolic diseases—including non-alcoholic fatty liver disease.

NLP leads to changes in genes involved in lipid metabolism in mice. Administering NLP reduces lipid levels, while disrupting its production alters lipid metabolism—reinforces its pivotal role in metabolic regulation. "It's beautiful to know the same peptide can achieve so many meritorious health effects, that in combination have the potential to help both human and animals.